Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturers.
BACKGROUND
The clinical efficacy of sublingual immunotherapy has been documented in numerous studies and meta-analyses and is argued to be a favored alternative to the subcutaneous route if allergic symptoms are treated with a high-dose therapy. What is still lacking is a 'conversion rate' between the biological activities of different allergen solutions to determine the one with the higher concentration.


METHODS
A randomized, double-blind, parallel-group study was done with three groups sensitized to the allergens birch, grass or house dust mite via skin prick test. Staloral in the concentrations 10, 100 and 300 IR and SLITone in the concentration of 1,000 STU per milliliter were used for a computer-based comparison of the geometric mean wheal sizes of the different solutions. For each patient, individual regression curves led to the calculation of a mean corresponding IR value for the SLITone solution.


RESULTS
A total of 47 patients took part in this clinical trial, most of whom were sensitized to more than one allergen. Values for birch (30 patients) showed that 1,000 STU corresponded to 77 IR, for grass (29 patients) 1,000 STU matched 78 IR and for house dust mite (30 patients) 1,000 STU matched 27 IR based on dose-response relationships. The Wilcoxon test showed that for all allergens the allergenic activity of the SLITone solution was significantly higher than the 10 IR solution and significantly lower than the 100- and 300-IR solutions.


CONCLUSIONS
We established a conversion rate between the two leading sublingual allergen solutions on the European market to compare different units of measurement.
Mösges
Ralph
R
Institute of Medical Statistics, Informatics, and Epidemiology, Medical Faculty, University of Cologne, Cologne, Germany. Ralph@Moesges.de
Pasch
Norbert
N
Schlierenkämper
Ulf
U
Lehmacher
Walter
W
D000286:Administration, Sublingual; D000328:Adult; D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology; D039741:Antigens, Dermatophagoides / Q000276:immunology; D029662:Betula / Q000276:immunology; D003888:Desensitization, Immunologic / Q000592:standards*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004345:Drug Industry; D005260:Female; D005858:Germany; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology*; D008297:Male; D006109:Poaceae / Q000276:immunology; D039981:Pyroglyphidae; D012015:Reference Standards; D012882:Skin Tests / Q000592:standards; D012996:Solutions
D000485:Allergens; D039741:Antigens, Dermatophagoides; D012996:Solutions